ITRS Acquires IP-Label to Strengthen Digital Experience Monitoring Capabilities and Expand European Presence
8.1.2026 15:00:00 CET | Business Wire | Press Release
ITRS, a leading provider of real-time IT monitoring and observability solutions for financial services and regulated industries, today announced it has signed a definitive agreement to acquire IP-Label, a premier Digital Experience Monitoring (DEM) provider headquartered in France. The acquisition strengthens ITRS's DEM capabilities and significantly expands its European market presence.
IP-Label serves 310+ enterprise customers across 25 countries through its AI-powered Ekara platform, which provides comprehensive synthetic transaction monitoring (STM), Real User Monitoring (RUM), and AI-driven incident triage to proactively identify and resolve performance issues before they affect customers or employees.
The Ekara platform's unique capabilities include monitoring of complex web applications, thick client applications, business-critical systems, mobile applications, self-service kiosk and virtual desktop infrastructure (VDI), with deployment options spanning cloud, self-hosted, and hybrid environments. In addition, IP-Label offers strong customer support capabilities through its Test Automation platform. These capabilities complement ITRS's existing DEM offering and market-leading infrastructure and application monitoring solutions.
"Digital experience has become the frontline of business performance and customer satisfaction. IP-Label brings enterprise-grade DEM technology that will accelerate our leadership in this critical category," said Ryan Terpstra, CEO of ITRS. "This acquisition accelerates our transformation into the leading observability platform for the world’s most demanding IT environments. Together with IP-Label, we will deliver holistic observability spanning IT infrastructure, application performance, and digital experience—all with the hybrid capability and configuration that complex and regulated industries require."
The company was recognized in Gartner's 2024 and 2025 Magic Quadrants for Digital Experience Monitoring (DEM). The acquisition significantly strengthens ITRS's position in the European IT market. IP-Label also brings an established partner ecosystem and global service partners.
"Joining ITRS provides IP-Label with the resources, scale, and observability platform to accelerate our growth trajectory while maintaining our commitment to innovation and customer success," said Philippe Borfiga, Co-CEO of IP-Label. "Together, we offer a highly cost-effective, end-to-end monitoring solution for digital services — from client experience to backend infrastructure. ITRS's deep expertise in serving large enterprises makes them the ideal partner for our next chapter of growth."
The transaction is expected to close in mid-January 2026, subject to customary closing conditions.
About ITRS
ITRS provides real-time monitoring and observability solutions that help financial institutions and enterprises ensure operational resilience, performance, and compliance. Trusted by leading banks and global multi-brand enterprises, ITRS enables teams to detect, diagnose, and resolve IT issues before they impact their customers or their business. Learn more at www.itrsgroup.com.
About IP-Label
Founded in 2001 and headquartered in La Garenne-Colombes, France, IP-Label is a leader in Digital Experience Monitoring. Through its AI-powered Ekara platform, IP-Label helps enterprises monitor and optimize the performance of their critical digital services across web, mobile, API, thick client applications, and VDI. The company serves 310+ customers across 25 countries and was recognized in Gartner's 2024 and 2025 Magic Quadrants for Digital Experience Monitoring. For more information, visit www.ip-label.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108333535/en/
Contacts
Media Contacts:
itrs@aspectusgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom